The ideal diabetes therapy: What will it look like? How close are we?

Clinical Diabetes

Volumn 30, Issue 2, 2012, Pages 44-53

  Rotenstein, Lisa S ^a   Kozak, Benjamin M ^a   Shivers, Joseph P ^a   Yarchoan, Mark ^b   Close, John ^a   Close, Kelly L ^a  

^a Close Concerns Inc   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BOVINE INSULIN; DAPAGLIFLOZIN; DEGLUDEC; DEGLUDECPLUS; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PIG INSULIN; PIOGLITAZONE; PLACEBO; RECOMBINANT HUMAN INSULIN; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TAK 875; TECHNOSPHERE INSULIN; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ARTICLE; BLADDER CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETES MELLITUS; DIABETIC PATIENT; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INFECTION RISK; INSULIN TREATMENT; LACTIC ACIDOSIS; NAUSEA; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHYSICIAN ATTITUDE; QT PROLONGATION; REIMBURSEMENT; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT GAIN;

EID: 84859826962     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.30.2.44     Document Type: Article

References (60)

1. National Diabetes Information Clearinghouse: National diabetes statistics, 2011 [article online]. Available from: http://diabetes.niddk.nih.gov/dm/pubs/ statistics/#Complications. Accessed 19 December 2011.
2. American Association of Clinical Endocrinologists: State of Diabetes Complications in America. Jacksonville, Fla., American Association of Clinical Endocrinologists, 2007.
3. U.S. Food and Drug Administration: Guidance for industry: diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [article online]. Available from http://www. pharmacy.arizona.edu/sites/default/files/ Guidance_for_Industry.pdf. Accessed 12 January 2012.
4. Gualandi-Signorini AM, Giorgi G: Insulin formulations: a review. Eur Rev Med Pharmacol Sci 5:73-83, 2001.
5. Joshi SR, Parikh RM, Das AK: Insulin history, biochemistry, physiology and pharmacology. J Assoc Physicians India 55:19-25, 2007.
6. Siebenhofer A, Plank J, Berghold A: Short-acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2:CD003287, 2006.
7. Little S, Shaw J, Home P: Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther 13:S53-S64, 2011.
8. Hirsch IB: Insulin analogues. N Engl J Med 352:174-183, 2005.
9. Garber AJ, Ligthelm R, Christiansen JS, Liebl A: Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 9:630-639, 2007.
10. Choe C, Edelman S: New therapeutic options for treating type 2 diabetes: a review of insulin analogs and premixed insulin analogs. J Natl Med Assoc 99:357-360, 363-367, 2007.
11. Bosi E: Metformin: the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab 11:3-8, 2009.
12. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203, 2009.
13. Phillips BB: Managing therapy and adverse effects with anti-hyperglycemic agents: a focus on metformin and acarbose. In Managing the Patient with Type II Diabetes. Wilson AL, Ed. Gaithersburg, Md., Jones & Bartlett Learning, 1997, p. 69-78.
14. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 163:2594-2602, 2003.
15. Lorenzati B, Zucco C, Miglietta S, Lamberti F, Bruno G: Oral hypoglycemic drugs: pathophysiological basis of their mechanism of action. Pharmaceuticals (Basel) 3:3005-3020, 2010.
16. Kahn SE, Haffner SM, Heise M, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443, 2006.
17. Accili D: Mechanisms of β-cell failure in the pathogenesis of type 2 diabetes. Drug Dev Res 69:111-115, 2008.
18. Pratley RE, Gilbert M: Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 5:73-94, 2008.
19. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705, 2006.
20. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492-498, 1986.
21. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52, 1986.
22. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723, 2001.
23. Holst JJ: Pharmacology of GLP-1-based therapies. Brit J Diabetes Vasc Dis 8:S10-S18, 2008.
24. Garber A: An overview of incretin clinical trials. J Fam Pract 57:S10-S18, 2008.
25. Drucker DJ, Dritselis A, Kirkpatrick P: Liraglutide. Nat Rev Drug Discov 9:267-268, 2010.
26. Blonde L, Russell-Jones D: The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 3:26-34, 2009.
27. John LE, Kane MP, Busch RS, Robert A: Expanded use of exenatide in the management of type 2 diabetes. Diabetes Spectrum 20:59-63, 2007.
28. Davidson J: Incorporating incretinbased therapies into clinical practice: differences between glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Mayo Clin Proc 85:S27-S37, 2010.
29. Pratley RE, Salsali A: Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 23:919-931, 2007.
30. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG: Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 34:369-374, 2011.
31. Amori RE, Lau J, Pittas AG: Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and metaanalysis. JAMA 298:194-206, 2007.
32. Goldstein BJ: Current views on the mechanism of action of thiazolidinedione insulin sensitizers. Diabetes Technol Ther 1:267-275, 1999.
33. Stafford JM, Elasy T: Treatment update: thiazolidenediones in combination with metformin for the treatment of type 2 diabetes. Vasc Health Risk Manag 3:503-510, 2007.
34. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR: Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820-825, 2008.
35. U.S. Food and Drug Administration: Avandia (rosiglitazone): REMS: risk of cardiovascular events [article online]. Available from: http://www.fda.gov/ Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ ucm226994.htm. Accessed 20 December 2011.
36. U.S. Food and Drug Administration: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer [article online]. Available from: http:// www.fda.gov/Drugs/DrugSafety/ucm259150. htm. Accessed 18 December 2011.
37. Aroda VR, DeYoung MB: Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes. Postgrad Med 123:228-238, 2011.
38. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240-1250, 2008.
39. Buse JB: Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomized, open-label study. Oral presentation (OP-13) presented at the 47th Annual Meeting of the European Association for the Study of Diabetes, 12-16 September 2011, in Lisbon, Portugal.
40. Taylor K, Gurney K, Han J, Pencek R, Walsh B, Trautmann M: Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 11:9, 2011.
41. Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K, Trautmann M, Shen LZ, Porter LE: DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33:1255-1261, 2010.
42. Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE: Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376:431-439, 2010.
43. Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, Taylor K: DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 28:705-714, 2011.
44. Russell-Jones D: Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes. Oral presentation (280-OR) presented at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June, 2011 in San Diego, Calif.
45. Macconell L, Malloy J, Huang W, Cirincione B, Shen L, Porter L: Safety and efficacy of once-monthly exenatide over 20 weeks in patients with type 2 diabetes. Poster presentation (46-LB) presented at 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, in San Diego, Calif.
46. Tahrani AA, Barnett AH: Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. Diabetes Ther 1:45-56, 2010.
47. Ferrannini E, Ramos S, Salsali A, Tang W: Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise. Diabetes 33:2217-2224, 2010.
48. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M: Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 12:510-516, 2010.
49. Langkilde AM: A meta-analysis of cardiovascular outcomes in clinical trials of dapagliflozin. Oral presentation (No. 8947) at Scientific Sessions of the American Heart Association, 12-16 November 2011, Orlando, Fla.
50. U.S. Food and Drug Administration: Document; NDA 202293: dapagliflozin tablets 5 and 10 mg: advisory committee meeting. Silver Spring, Md., U.S. Food and Drug Administration, 2011.
51. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Haahr H: Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Poster presentation (37-LB) presented at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, in San Diego, Calif.
52. Meneghini L, Atkin S, Bain S, Blonde L, Raz I, Begtrup K, Johansen T, Birkeland KI: Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes: Poster presentation (35-LB) at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, in San Diego, Calif.
53. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmuseen S, Haahr H: The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state. Poster presentation (960-P) presented at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, in San Diego, Calif.
54. Heller S: Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in type 1 diabetes. Oral presentation (70-OR) presented at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, in San Diego, Calif.
55. Garber A: Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in people with type 2 diabetes. Oral presentation (74-OR) presented at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, in San Diego, Calif.
56. Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang P-C, Petrucci RE, Boss AH, Richardson PC: Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 375:2244-2253, 2010.
57. Amin N, Boss A, Petrucci R, Phillips M, Richardson P: Pulmonary functions (over 2 years) in diabetic subjects treated with AFRESA or usual antidiabetic treatment. Poster presentation (570-P) presented at the 69th Scientific Sessions of the American Diabetes Association, 5-9 June 2009, in New Orleans, La.
58. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, Leifke E: TAK-875 versus placebo or glimepiride in type 2 diabete mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. Published electronically ahead of print on 27 February 2012. (doi:10.1016/ S0140-6736(11)61879-5)
59. Araki T: TAK-875, a novel GPR40 agonist, improves both postprandial and fasting hyperglycemia in Japanese patients with type 2 diabetes. Oral presentation (312-OR) at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, in San Diego, Calif.
60. UnitedHealth Group Center for Health Reform and Modernization: The United States of Diabetes: Challenges and Opportunities in the Decade Ahead. Minnetonka, Minn., UnitedHealth Group Center for Health Reform and Modernization, 2010